AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month Period

By Reuters News

- AbbVie Inc. ABBV.N:

  • ABBVIE: IN PHASE 1 ABBV-295 STUDY, ALL DOSING REGIMENS RESULTED IN LS MEAN WEIGHT LOSS UP TO ABOUT 10% OVER 3-MONTH TREATMENT PERIOD

  • ABBVIE: 82.2% OF ALL ABBV-295 TREATED PARTICIPANTS REPORTED MILD ADVERSE EVENTS AS HIGHEST REPORTED AE SEVERITY


Further company coverage: ABBV.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk